Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings ...

Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but saw lower realized prices. Demand in the U.S. has far outpaced supply ...

Eli Lilly and Company (NYSE:LLY) has seen impressive growth in recent years, largely due to the success of its glucagon-like peptide ... sales of its blockbuster diabetes and obesity drugs.

The stock has performed exceptionally well in recent years, driven by the success of its glucagon ... “Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company that develops diabetes ...

Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared ... Connecticut's News Headlines newsletter. The company's quarterly ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past several ...